Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 3
1998 8
1999 3
2000 11
2001 6
2002 4
2003 5
2004 5
2005 3
2006 2
2008 1
2009 1
2010 1
2011 1
2012 4
2013 1
2014 1
2015 2
2016 3
2017 1
2019 1
2021 1
2022 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Results by year
Filters applied: . Clear all
Page 1
Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia.
Al-Samkari H, Soff GA. Al-Samkari H, et al. Expert Rev Hematol. 2021 May;14(5):437-448. doi: 10.1080/17474086.2021.1924053. Epub 2021 May 13. Expert Rev Hematol. 2021. PMID: 33926362 Review.
There is no FDA-approved agent available to manage CIT.Areas covered: This article covers the diagnosis, definitions, and clinical challenges of CIT, and then focuses on the therapeutics developed to manage CIT. The first-generation thrombopoietic agents (oprelvekin and re …
There is no FDA-approved agent available to manage CIT.Areas covered: This article covers the diagnosis, definitions, and clinical challenge …
Oprelvekin.
[No authors listed] [No authors listed] 2016 Jun 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2016 Jun 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643512 Free Books & Documents. Review.
Oprelvekin is a recombinant form of human interleukin 11, a cytokine that stimulates proliferation and maturation of bone marrow stem cells and megakaryocytes and is used to treat severe thrombocytopenia caused by chemotherapy. ...
Oprelvekin is a recombinant form of human interleukin 11, a cytokine that stimulates proliferation and maturation of bone marrow stem
Hematologic Growth Factors.
[No authors listed] [No authors listed] 2016 Aug 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2016 Aug 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644052 Free Books & Documents. Review.
Drug Class: Hematologic Growth Factors Drugs in the Subclass, Colony Stimulating Factors: Granulocyte Colony Stimulating Factors (G-CSF: Filgrastim and Pegfilgrastim), Granulocyte-Macrophage Colony Stimulating Factors (GM-CSF: Sargramostim) Drugs in the Subclass, Erythropoiesis S …
Drug Class: Hematologic Growth Factors Drugs in the Subclass, Colony Stimulating Factors: Granulocyte Colony Stimulating Factors (G-CSF: Fil …
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem.
Al-Samkari H. Al-Samkari H. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):286-295. doi: 10.1182/hematology.2022000374. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485134 Free PMC article. Review.
The only agent approved by the US Food and Drug Administration to manage CIT (oprelvekin) was voluntarily withdrawn from the market by the manufacturer, leaving few options for patients. ...
The only agent approved by the US Food and Drug Administration to manage CIT (oprelvekin) was voluntarily withdrawn from the market b …
Interleukin-11.
Dorner AJ, Goldman SJ, Keith JC Jr. Dorner AJ, et al. BioDrugs. 1997 Dec;8(6):418-29. doi: 10.2165/00063030-199708060-00002. BioDrugs. 1997. PMID: 18031104
Interleukin-11 (IL-11) is a cytokine which interacts with a variety of haemopoietic and non-haemopoietic cell types. Recombinant human IL-11 (rhIL-11; oprelvekin) is produced in Escherichia coli and differs from the naturally occurring protein only in the absence of the am …
Interleukin-11 (IL-11) is a cytokine which interacts with a variety of haemopoietic and non-haemopoietic cell types. Recombinant human IL-11 …
Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.
Wilde MI, Faulds D. Wilde MI, et al. BioDrugs. 1998 Aug;10(2):159-71. doi: 10.2165/00063030-199810020-00006. BioDrugs. 1998. PMID: 18020592
Oprelvekin is a recombinant human interleukin-11. Its predominant haemopoietic activity is stimulation of megakaryocytopoiesis. ...There was also at least a trend towards reduced time to platelet recovery in oprelvekin recipients. The efficacy of oprelvekin i
Oprelvekin is a recombinant human interleukin-11. Its predominant haemopoietic activity is stimulation of megakaryocytopoiesis. ...Th
Incorporating new modalities into practice guidelines: platelet growth factors.
Rubenstein EB, Elting L. Rubenstein EB, et al. Oncology (Williston Park). 1998 Nov;12(11A):381-6. Oncology (Williston Park). 1998. PMID: 10028521 Review.
In placebo-controlled trials of patients with solid tumors receiving dose-intensive chemotherapy, 68% of oprelvekin recipients escaped transfusion altogether, compared with only 41% of those who received a placebo. ...Although clinical trials provide evidence about how man …
In placebo-controlled trials of patients with solid tumors receiving dose-intensive chemotherapy, 68% of oprelvekin recipients escape …
Oprelvekin. Genetics Institute.
Sitaraman SV, Gewirtz AT. Sitaraman SV, et al. Curr Opin Investig Drugs. 2001 Oct;2(10):1395-400. Curr Opin Investig Drugs. 2001. PMID: 11890354 Review.
Genetics Institute has developed and launched oprelvekin (rhIL-11; Neumega), a recombinant form of human IL-11. In November 1997, the FDA cleared oprelvekin for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions followi …
Genetics Institute has developed and launched oprelvekin (rhIL-11; Neumega), a recombinant form of human IL-11. In November 1997, the …
Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection.
Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt VR. Dahal S, et al. Mediterr J Hematol Infect Dis. 2017 Mar 1;9(1):e2017019. doi: 10.4084/MJHID.2017.019. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 28293407 Free PMC article. Review.
Thrombopoietin-mimetic agents, in particular, eltrombopag and romiplostim, have been shown to be safe and effective for HCV-related thrombocytopenia in various studies, and they increase platelet count without eliciting any immunogenicity Other treatment modalities including newe …
Thrombopoietin-mimetic agents, in particular, eltrombopag and romiplostim, have been shown to be safe and effective for HCV-related thromboc …
Side effects of cytokines approved for therapy.
Baldo BA. Baldo BA. Drug Saf. 2014 Nov;37(11):921-43. doi: 10.1007/s40264-014-0226-z. Drug Saf. 2014. PMID: 25270293 Free PMC article. Review.
In the hematopoietin family, approved cytokines are aldesleukin (rhIL-2), oprelvekin (rhIL-11), filgrastim and tbo-filgrastim (rhG-CSF), sargramostim (rhGM-CSF), metreleptin (rh-leptin) and the rh-erythropoietins, epoetin and darbepoietin alfa. ...
In the hematopoietin family, approved cytokines are aldesleukin (rhIL-2), oprelvekin (rhIL-11), filgrastim and tbo-filgrastim (rhG-CS …
70 results